Surrozen Files Investigational New Drug Application for SZN-8141 in Diabetic Macular Edema

10:40 AM EDT, 09/08/2026 (MT Newswires) -- Surrozen (SRZN) said Tuesday that it submitted an investigational new drug application to the US Food and Drug Administration seeking to evaluate SZN-8141 as a potential treatment for diabetic macular edema. The company said it expects to launch a phase 1b/2a study in diabetic macular edema patients by the end of 2026, and anticipates initial data in H2 of 2027. Surrozen said preclinical studies showed that SZN-8141 delivered "superior" biological activity in reducing neovascularization and promoting retinal revascularization in a rodent model of retinal vascular disease, compared with either Wnt agonist or anti-VEGF monotherapy. SZN-8141 also demonstrated further reductions in vascular leakage than anti-VEGF therapy in a rodent model of neovascular age-related macular degeneration, the company said. Shares of the company were down 2% in Tuesday trading. Price: 22.31, Change: -0.45, Percent Change: -1.98